Related Experiment Video
Updated: Jun 21, 2025

Polygraphic Recording Procedure for Measuring Sleep in Mice
Published on: January 25, 2016
Orexin receptor antagonist increases fat oxidation and suppresses protein catabolism during sleep in humans
Insung Park1, Rikako Yoshitake2, Kazuki Kioka2
1International Institute for Integrative Sleep Medicine, University of Tsukuba, Tsukuba, Ibaraki 305-8575, Japan.
Abstract:
Suvorexant is an orexin receptor antagonist that targets the wake-promoting system. Orexin is also known to regulate energy metabolism in rodents, but its role in humans remains largely unknown. Here, we assessed the effect of suvorexant (20 mg) on energy metabolism during sleep and shortly after awakening in a randomized, double-blind, placebo-controlled, crossover study in 14 healthy men. Suvorexant increased rapid eye movement (REM) but decreased nonrapid eye movement (NREM) stage 1. Energy expenditure during wake after sleep onset (WASO) was higher than that during NREM and REM sleep in the placebo but not in the suvorexant trial, suggesting that the increase in energy expenditure during WASO was due to an activation of the orexin system. Fat oxidation during sleep increased, and its effect remained after waking the next morning. Suvorexant decreased protein catabolism but did not affect overall energy expenditure. The orexin system may affect fat oxidation independent of its roles in sleep regulation in humans.
Insights
Suvorexant, an orexin receptor antagonist, altered sleep stages and fat metabolism in healthy men. It increased fat oxidation during sleep and reduced protein breakdown, suggesting orexin
Area of Science:
- Neuroscience
- Metabolic research
- Sleep science
Background:
- Orexin signaling regulates wakefulness and is implicated in energy metabolism in rodents.
- The role of orexin in human energy metabolism, particularly during sleep and post-awakening, is not well understood.
Purpose of the Study:
- To investigate the effects of suvorexant, an orexin receptor antagonist, on energy metabolism during sleep and shortly after awakening in healthy men.
- To explore the potential role of the orexin system in regulating human energy expenditure and substrate oxidation.
Main Methods:
- A randomized, double-blind, placebo-controlled, crossover study involving 14 healthy male participants.
- Administration of suvorexant (20 mg) or placebo, with assessment of sleep stages (REM, NREM) and energy expenditure.
- Measurement of substrate oxidation (fat and protein) during sleep and wakefulness after sleep onset (WASO).
Main Results:
- Suvorexant increased REM sleep and decreased NREM stage 1 sleep.
- Energy expenditure during WASO was elevated with placebo but not suvorexant, suggesting orexin's role in wake-related energy expenditure.
- Fat oxidation during sleep increased with suvorexant and persisted post-awakening; protein catabolism decreased, but overall energy expenditure remained unchanged.
Conclusions:
- The orexin system influences energy expenditure during wakefulness after sleep onset in humans.
- Suvorexant administration impacts fat oxidation during sleep, potentially independent of its sleep-regulating functions.
- These findings suggest a distinct role for the orexin system in modulating human metabolic processes beyond sleep control.
Related Concept Videos
Sleep-Wake Cycles
NREM Sleep
NREM sleep comprises four progressive stages that seamlessly merge:
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Regulation of Food Intake
Management of Insomnia
Insufficient Sleep and Sleep Deprivation
Sleep deprivation is a more severe form of sleep loss...
Narcolepsy

